Wessels F
Inneren Abteilung, Franziskus Krankenhaus, Essen, West Germany.
Am Heart J. 1991 Jan;121(1 Pt 2):299-303. doi: 10.1016/0002-8703(91)90862-c.
The antihypertensive efficacy and safety of doxazosin and enalapril were compared in the general practice setting (n = 54). Both agents produced comparable, statistically significant (p less than 0.05) reductions in mean blood pressure with no clinically relevant changes in heart rate. Side effects in the two groups were mild or moderate and disappeared or were tolerated with continued treatment. Doxazosin, in contrast to enalapril, produced a significant (p less than 0.05) reduction in the total serum cholesterol concentration, a reduction in the level of triglycerides, and a favorable increase in the high-density lipoprotein/total cholesterol ratio. The reduction in calculated coronary heart disease risk produced by doxazosin (-27.58%) was highly significant (p less than 0.0002) and greater than that produced by enalapril (-18.49% p less than 0.02).
在普通医疗环境中（n = 54）比较了多沙唑嗪和依那普利的降压疗效及安全性。两种药物均使平均血压产生了具有可比性且具有统计学意义（p < 0.05）的降低，心率无临床相关变化。两组的副作用均为轻度或中度，且在持续治疗过程中消失或可耐受。与依那普利相反，多沙唑嗪使总血清胆固醇浓度显著降低（p < 0.05），甘油三酯水平降低，高密度脂蛋白/总胆固醇比值出现有利升高。多沙唑嗪使计算得出的冠心病风险降低（-27.58%）具有高度统计学意义（p < 0.0002），且大于依那普利（-18.49%，p < 0.02）所产生的降低幅度。
